Literature DB >> 913027

Monoacetylhydrazine as a metabolite of isoniazid in man.

J A Timbrell, J M Wright, T A Baillie.   

Abstract

The potent hepatotoxin, acetylhydrazine (monoacetylhydrazine), has been identified by gas chromatography-mass spectrometry as a urinary metabolite of isoniazid in man. Using a specific gas chromatographic assay procedure for acetylhydrazine, the urinary excretion of this metabolite in volunteers given a 300-mg dose of isoniazid was found to be 1.8 +/- 0.4% and 2.5 +/- 0.5% of the dose in the rapid and slow acetylators, respectively. In the same subjects the urinary excretion of diacetylhydrazine was significantly greater in the rapid acetylators, 23.0 +/- 2.0%, than in the slow acetylators, 4.9 +/- 0.9%. The results suggests that only part of the acetylhydrazine formed as a metabolite of isoniazid is excreted in the urine as acetylhydrazine and diacetylhydrazine and that a substantial proportion of the acetylhydrazine formed is further metabolized, possibly through the microsomal enzyme pathway known to be responsible for hepatotoxicity in experimental animals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 913027     DOI: 10.1002/cpt1977225part1602

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.

Authors:  Supharat Suvichapanich; Sukanya Wattanapokayakit; Taisei Mushiroda; Hideki Yanai; Charoen Chuchottawon; Tassawan Kantima; Supalert Nedsuwan; Wimon Suwankesawong; Cholticha Sonsupap; Roongkarn Pannarunothai; Sukanya Tumpattanakul; Warawut Bamrungram; Achara Chaiwong; Surakameth Mahasirimongkol; Sasithorn Mameechai; Weerapat Panthong; Nantawan Klungtes; Amara Munsoo; Udomrat Chauychana; Molrudee Maneerat; Koya Fukunaga; Yosuke Omae; Katsushi Tokunaga
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

Authors:  E Peretti; G Karlaganis; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Drug hepatotoxicity.

Authors:  J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

5.  Medical Staff Conference. Drug-induced liver disease.

Authors: 
Journal:  West J Med       Date:  1979-07

Review 6.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 7.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

8.  Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.

Authors:  Y Horai; T Ishizaki; T Sasaki; G Koya; K Matsuyama; S Iguchi
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

9.  Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Authors:  Michael J Hearn; Michael H Cynamon; Michaeline F Chen; Rebecca Coppins; Jessica Davis; Helen Joo-On Kang; Abigail Noble; Becky Tu-Sekine; Marianne S Terrot; Daniella Trombino; Minh Thai; Eleanor R Webster; Rebecca Wilson
Journal:  Eur J Med Chem       Date:  2009-05-21       Impact factor: 6.514

Review 10.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.